{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:34:59Z","timestamp":1783524899373,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00120-026-02775-x","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T11:01:23Z","timestamp":1770634883000},"page":"278-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostik und Therapie von Urothelkarzinomen der Harnblase mit besonderer Histologie","Diagnosis and treatment of urothelial carcinoma of the bladder with divergent histology"],"prefix":"10.1007","volume":"65","author":[{"given":"Nadine Therese","family":"Gaisa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"issue":"1","key":"2775_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk\u00a0M, Burger\u00a0M, Capoun\u00a0O, Cohen\u00a0D, Comp\u00e9rat\u00a0EM, Dominguez Escrig\u00a0JL, Gontero\u00a0P, Liedberg\u00a0F, Masson-Lecomte\u00a0A, Mostafid\u00a0AH, Palou\u00a0J, van Rhijn\u00a0BWG, Roupr\u00eat\u00a0M, Shariat\u00a0SF, Seisen\u00a0T, Soukup\u00a0V, Sylvester\u00a0RJ (2022) European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 81(1):75\u201394","journal-title":"Eur Urol"},{"issue":"1","key":"2775_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes\u00a0J, Max Bruins\u00a0H, Carri\u00f3n\u00a0A, Cathomas\u00a0R, Comp\u00e9rat\u00a0E, Efstathiou\u00a0JA, Fietkau\u00a0R, Gakis\u00a0G, Lorch\u00a0A, Martini\u00a0A, Mertens\u00a0LS, Meijer\u00a0RP, Milowsky\u00a0MI, Neuzillet\u00a0Y, Panebianco\u00a0V, Redlef\u00a0J, Rink\u00a0M, Rouanne\u00a0M, Thalmann\u00a0GN, S\u00e6bj\u00f8rnsen\u00a0S, Veskim\u00e4e\u00a0E, van der Heijden\u00a0AG (2024) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol 85(1):17\u201331","journal-title":"Eur Urol"},{"key":"2775_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","volume":"82","author":"GJ Netto","year":"2022","unstructured":"Netto\u00a0GJ, Amin\u00a0MB, Berney\u00a0DM, Comp\u00e9rat\u00a0EM, Gill\u00a0AJ, Hartmann\u00a0A, Menon\u00a0S, Raspollini\u00a0MR, Rubin\u00a0MA, Srigley\u00a0JR et\u00a0al (2022) The 2022World Health Organization classification of tumors of the urinary system and male genital organs\u2014Part\u00a0B:\u00a0Prostate and urinary tract tumors. Eur Urol 82:469\u2013482","journal-title":"Eur Urol"},{"key":"2775_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrurol.2017.125","volume":"14","author":"M Moschini","year":"2017","unstructured":"Moschini\u00a0M, D\u2019 Andrea\u00a0D, Korn\u00a0S, Irmak\u00a0Y, Soria\u00a0F, Comp\u00e9rat\u00a0E, Shariat\u00a0SF (2017) Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 14:651\u2013668","journal-title":"Nat Rev Urol"},{"key":"2775_CR5","first-page":"18.e15","volume":"33","author":"MF Monn","year":"2015","unstructured":"Monn\u00a0MF, Kaimakliotis\u00a0HZ, Pedrosa\u00a0JA, Cary\u00a0KC, Bihrle\u00a0R, Cheng\u00a0L, Koch\u00a0MO (2015) Contemporary bladder cancer: Variant histology may be a significant driver of disease. Urol. Oncol. Semin. Orig. Investig 33:18.e15\u201318.e20","journal-title":"Urol. Oncol. Semin. Orig. Investig"},{"key":"2775_CR6","doi-asserted-by":"crossref","unstructured":"Aron, M.\u00a0Variant histology in bladder cancer\u2014Current understanding of pathologic subtypes. Curr. Urol. Rep. 2019, 20, 80.","DOI":"10.1007\/s11934-019-0949-6"},{"key":"2775_CR7","volume":"34","author":"JT Brown","year":"2023","unstructured":"Brown\u00a0JT, Narayan\u00a0VM, Joshi\u00a0SS, Harik\u00a0L, Jani\u00a0AB, Bilen\u00a0MA (2023) Challenges and opportunities in the management of non-urothelial bladder cancers. Cancer Treat. Res. Commun 34:100663","journal-title":"Cancer Treat. Res. Commun"},{"key":"2775_CR8","series-title":"WHO classification of tumours series","volume-title":"Urinary and male genital tumours","author":"WHO Classification of Tumours Editorial Board","year":"2022","unstructured":"WHO Classification of Tumours Editorial Board (2022) Urinary and male genital tumours, 5\u00a0edn. WHO classification of tumours series, vol 8. International Agency for Research on Cancer, Lyon (France)","edition":"5"},{"key":"2775_CR9","unstructured":"PMID:23707452"},{"key":"2775_CR10","unstructured":"PMID: 39124615"},{"key":"2775_CR11","unstructured":"29885409"},{"key":"2775_CR12","unstructured":"PMID:39097190"},{"key":"2775_CR13","unstructured":"PMID:38323607"},{"key":"2775_CR14","unstructured":"PMID:30895340"},{"key":"2775_CR15","unstructured":"PMID: 40471793"},{"key":"2775_CR16","unstructured":"PMID:40757456"},{"key":"2775_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","volume":"6","author":"N Lobo","year":"2020","unstructured":"Lobo\u00a0N, Shariat\u00a0SF, Guo\u00a0CC, Fernandez\u00a0MI, Kassouf\u00a0W, Choudhury\u00a0A et\u00a0al (2020) What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus 6:653\u2013663","journal-title":"Eur Urol Focus"},{"key":"2775_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1464-410X.2008.08241.x","volume":"103","author":"M Mukesh","year":"2009","unstructured":"Mukesh\u00a0M, Cook\u00a0N, Hollingdale\u00a0AE, Ainsworth\u00a0NL, Russell\u00a0SG (2009) Small cell carcinoma of the urinary bladder: A 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int 103:747\u2013752","journal-title":"BJU Int"},{"key":"2775_CR19","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.2008.19.0256","volume":"27","author":"AO Siefker-Radtke","year":"2009","unstructured":"Siefker-Radtke\u00a0AO, Kamat\u00a0AM, Grossman\u00a0HB, Williams\u00a0DL, Qiao\u00a0W, Thall\u00a0PF, Dinney\u00a0CP, Millikan\u00a0RE (2009) Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide\/doxorubicin and etoposide\/cisplatin in small cell urothelial cancer. J\u00a0Clin Oncol 27:2592\u20132597","journal-title":"J Clin Oncol"},{"key":"2775_CR20","unstructured":"PMID:31054897"},{"key":"2775_CR21","unstructured":"PMID:24582117"},{"key":"2775_CR22","unstructured":"PMID:26901067"},{"key":"2775_CR23","unstructured":"PMID:17936803"},{"key":"2775_CR24","unstructured":"PMID:25029121"},{"key":"2775_CR25","unstructured":"PMID:27031776"},{"key":"2775_CR26","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761139s032s035lbl.pdf"},{"key":"2775_CR27","unstructured":"https:\/\/dailyreporter.esmo.org\/esmo-congress-2025\/genitourinary-cancers\/disitamab-vedotin-plus-immunotherapy-almost-doubles-overall-survival-in-advanced-her2-expressing-urothelial-cancer"},{"issue":"3","key":"2775_CR28","doi-asserted-by":"publisher","first-page":"71.e1","DOI":"10.1016\/j.urolonc.2023.12.005","volume":"42","author":"Z Lone","year":"2024","unstructured":"Lone\u00a0Z, Benidir\u00a0T, Wood\u00a0A, Campbell\u00a0RA, Alaghehbandan\u00a0R, Li\u00a0J, Haber\u00a0GP, Eltemamy\u00a0M, Haywood\u00a0SC, Weight\u00a0CJ, Lee\u00a0BH, Almassi\u00a0N (2024) Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology. Urol Oncol 42(3):71.e1\u201371.e7","journal-title":"Urol Oncol"},{"issue":"7","key":"2775_CR29","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00345-016-1962-8","volume":"35","author":"W Sui","year":"2017","unstructured":"Sui\u00a0W, Matulay\u00a0JT, Onyeji\u00a0IC, Theofanides\u00a0MC, James\u00a0MB, RoyChoudhury\u00a0A, Wenske\u00a0S, DeCastro\u00a0GJ (2017) Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. World J Urol 35(7):1055\u20131061","journal-title":"World J Urol"},{"key":"2775_CR30","first-page":"366","volume":"5","author":"M Malla","year":"2016","unstructured":"Malla\u00a0M, Wang\u00a0JF, Trepeta\u00a0R, Feng\u00a0A, Wang\u00a0J (2016) Sarcomatoid carcinoma of the urinary bladder. Clin Genitorurin Cancer 5:366\u2013372","journal-title":"Clin Genitorurin Cancer"},{"key":"2775_CR31","doi-asserted-by":"crossref","unstructured":"Wang J, Wang FW, Langrange CA, Hemstreet Iii, Kessinger A. Clinical features of sarcomatoid (carcinosarkoma) of the urinry bladder: analysis of 221 cases. Sarcoma 2010; article ID 454792","DOI":"10.1155\/2010\/454792"},{"issue":"6","key":"2775_CR32","doi-asserted-by":"publisher","first-page":"275.e1","DOI":"10.1016\/j.urolonc.2022.02.004","volume":"40","author":"F Dursun","year":"2022","unstructured":"Dursun\u00a0F, Elshabrawy\u00a0A, Wang\u00a0H, Wu\u00a0S, Liss\u00a0MA, Kaushik\u00a0D, Grosser\u00a0D, Svatek\u00a0RS, Mansour\u00a0AM (2022) Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy. Urol Oncol 40(6):275.e1\u2013275.e10","journal-title":"Urol Oncol"},{"issue":"4","key":"2775_CR33","doi-asserted-by":"publisher","first-page":"266.e1","DOI":"10.1016\/j.urolonc.2024.09.005","volume":"43","author":"AM Wood","year":"2025","unstructured":"Wood\u00a0AM, Benidir\u00a0T, Campbell\u00a0R, Li\u00a0J, Lone\u00a0Z, Haywood\u00a0S, Eltemamy\u00a0M, Weight\u00a0CJ, Haber\u00a0GP, Almassi\u00a0N, Alaghehbandan\u00a0R (2025) Quantification of micropapillary component on transurethral resection is associated with likelihood of occult lymph node metastasis at radical cystectomy. Urol Oncol 43(4):266.e1\u2013266.e7","journal-title":"Urol Oncol"},{"key":"2775_CR34","unstructured":"Mally AD, Tin AL, Lee JK, Satasivam P, Cha EK, Donat SM, Herr HW, Bochner BH, Sjoberg DD, Dalbagni G. Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder. Clin Genitourin Cancer. 2017 Jul 14:S1558\u20137673(17)30199\u20114"},{"issue":"4","key":"2775_CR35","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/JU.0000000000001855","volume":"206","author":"NH Chakiryan","year":"2021","unstructured":"Chakiryan\u00a0NH, Jiang\u00a0DD, Gillis\u00a0KA, Green\u00a0E, Hajiran\u00a0A, Hugar\u00a0L, Zemp\u00a0L, Zhang\u00a0J, Jain\u00a0R, Chahoud\u00a0J, Poch\u00a0M, Manley\u00a0BJ, Li\u00a0R, Sexton\u00a0W, Gilbert\u00a0SM (2021) Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J\u00a0Urol 206(4):924\u2013932","journal-title":"J Urol"},{"issue":"2","key":"2775_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.clgc.2023.10.006","volume":"22","author":"RA Campbell","year":"2024","unstructured":"Campbell\u00a0RA, Khanna\u00a0A, Boorjian\u00a0SA, Knorr\u00a0J, Cox\u00a0R, Nicholas\u00a0M, Cheville\u00a0J, Sharma\u00a0V, Murthy\u00a0PB, Tarrell\u00a0R, Thapa\u00a0P, Tollefson\u00a0MK, Thompson\u00a0RH, Frank\u00a0I, Karnes\u00a0RJ, Haber\u00a0GP, Lee\u00a0B (2024) Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy. Clin Genitourin Cancer 22(2):157\u2013163.e1","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2775_CR37","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/j.clgc.2021.11.011","volume":"20","author":"M Fu","year":"2022","unstructured":"Fu\u00a0M, Klose\u00a0C, Sparks\u00a0A, Whalen\u00a0M (2022) Impact of Variant Histology on Occult Nodal Metastasis after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Review of the National Cancer Database. Clin Genitourin Cancer 20(2):e135\u2013e139","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"2775_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/bju.15428","volume":"129","author":"N Almassi","year":"2022","unstructured":"Almassi\u00a0N, Vertosick\u00a0EA, Sjoberg\u00a0DD, Wong\u00a0NC, Huang\u00a0C, Pietzak\u00a0EJ, Cha\u00a0EK, Donahue\u00a0TF, Dalbagni\u00a0G, Bochner\u00a0BH, Iyer\u00a0G, Rosenberg\u00a0JE, Bajorin\u00a0DF, Al-Ahmadie\u00a0H, Goh\u00a0AC (2022) Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. BJU Int 129(4):463\u2013469","journal-title":"BJU Int"},{"key":"2775_CR39","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1464-410X.2010.09900.x","volume":"108","author":"E Scosyrev","year":"2011","unstructured":"Scosyrev\u00a0E, Ely\u00a0BW, Messing\u00a0EM et\u00a0al (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108:693\u2013699","journal-title":"BJU Int"},{"issue":"4","key":"2775_CR40","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/JU.0000000000003836","volume":"211","author":"Y Allory","year":"2024","unstructured":"Allory\u00a0Y, Culine\u00a0S, Krucker\u00a0C, Fontugne\u00a0J, Harter\u00a0V, Pfister\u00a0C (2024) Impact of Divergent Differentiation and\/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial. J\u00a0Urol 211(4):564\u2013574","journal-title":"J Urol"},{"key":"2775_CR41","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1002\/cncr.30907","volume":"123","author":"MW Vetterlein","year":"2017","unstructured":"Vetterlein\u00a0MW, Mullane\u00a0S, Seisen\u00a0T et\u00a0al (2017) Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer 123:4346\u20134355","journal-title":"Cancer"},{"key":"2775_CR42","doi-asserted-by":"publisher","first-page":"E325","DOI":"10.1111\/j.1464-410X.2012.11751.x","volume":"111","author":"JJ Meeks","year":"2013","unstructured":"Meeks\u00a0JJ, Taylor\u00a0JM, Matsushita\u00a0K et\u00a0al (2013) Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int 111:E325\u2013E330","journal-title":"BJU Int"},{"key":"2775_CR43","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bju.13689","volume":"119","author":"MI Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez\u00a0MI, Williams\u00a0SB, Willis\u00a0DL et\u00a0al (2017) Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int 119:684\u2013691","journal-title":"BJU Int"},{"issue":"1","key":"2775_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/biomedicines13010086","volume":"13","author":"WA Kwon","year":"2025","unstructured":"Kwon\u00a0WA, Seo\u00a0HK, Song\u00a0G, Lee\u00a0MK, Park\u00a0WS (2025) Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development. Biomedicines 13(1):86\u201386","journal-title":"Biomedicines"},{"issue":"2","key":"2775_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.euf.2024.05.015","volume":"10","author":"E Day","year":"2024","unstructured":"Day\u00a0E, Gavira\u00a0J, Tapia\u00a0JC, Anguera\u00a0G, Maroto\u00a0P (2024) What About Variant Histologies in Bladder Cancer? Eur Urol Focus 10(2):227\u2013230","journal-title":"Eur Urol Focus"},{"issue":"2","key":"2775_CR46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/JU.0000000000003778","volume":"211","author":"A Sood","year":"2024","unstructured":"Sood\u00a0A, Rudzinski\u00a0JK, Labbate\u00a0CV, Hensley\u00a0PJ, Bree\u00a0KK, Guo\u00a0CC, Alhalabi\u00a0O, Campbell\u00a0MT, Siefker-Radtke\u00a0AO, Navai\u00a0N, Dinney\u00a0CPN, Gao\u00a0J, Kamat\u00a0AM (2024) Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J\u00a0Urol 211(2):241\u2013255","journal-title":"J Urol"},{"key":"2775_CR47","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi\u00a0A, Raggi\u00a0D, Gallina\u00a0A et\u00a0al (2020) Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. Eur Urol 77:439\u2013446","journal-title":"Eur Urol"},{"issue":"5","key":"2775_CR48","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.eururo.2025.04.008","volume":"88","author":"CE Chu","year":"2025","unstructured":"Chu\u00a0CE, Chen\u00a0Z, Whiting\u00a0K, Ostrovnaya\u00a0I, Lenis\u00a0AT, Clinton\u00a0TN, Rammal\u00a0R, Ozcan\u00a0GG, Akbulut\u00a0D, Basar\u00a0M, Chen\u00a0JF, Chen\u00a0YB, Gopalan\u00a0A, Fine\u00a0SW, Tickoo\u00a0SK, Arcila\u00a0M, Brannon\u00a0AR, Berger\u00a0MF, Cha\u00a0EK, Goh\u00a0AC, Donahue\u00a0TF, Bajorin\u00a0DF, Teo\u00a0MY, Rosenberg\u00a0JE, Iyer\u00a0G, Pietzak\u00a0EJ, Bochner\u00a0BH, Reuter\u00a0VE, Sarungbam\u00a0J, Solit\u00a0DB, Al-Ahmadie\u00a0H (2025) Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma. Eur Urol 88(5):472\u2013481","journal-title":"Eur Urol"},{"key":"2775_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JU.0000000000000761","volume":"204","author":"NJ Miller","year":"2020","unstructured":"Miller\u00a0NJ, Khaki\u00a0AR, Diamantopoulos\u00a0LN, Bilen\u00a0MA, Santos\u00a0V, Agarwal\u00a0N, Morales-Barrera\u00a0R, Devitt\u00a0M, Nelson\u00a0A, Hoimes\u00a0CJ et\u00a0al (2020) Histological subtypes and response to PD-1\/PD-L1 blockade in advanced urothelial cancer: A retrospective study. J. Urol 204:63\u201370","journal-title":"J. Urol"},{"key":"2775_CR50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.652","volume":"42","author":"T Jindal","year":"2024","unstructured":"Jindal\u00a0T, Jiang\u00a0CY, Alhalabi\u00a0O, Nguyen\u00a0CB, Nizam\u00a0A, Basu\u00a0A, Bilen\u00a0MA, Zakharia\u00a0Y, Milowsky\u00a0MI, Brown\u00a0JR et\u00a0al (2024) Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study. J. Clin. Oncol 42:652","journal-title":"J. Clin. Oncol"},{"issue":"4","key":"2775_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102356","volume":"23","author":"DR Bakaloudi","year":"2025","unstructured":"Bakaloudi\u00a0DR, Talukder\u00a0R, Enright\u00a0T, Leary\u00a0JB, Makrakis\u00a0D, Diamantopoulos\u00a0LN, Hobeika\u00a0C, Thomas\u00a0VM, Swami\u00a0U, Zakopoulou\u00a0R, Bamias\u00a0A, Brown\u00a0JR, Pinato\u00a0DJ, Latchford\u00a0C, Jindal\u00a0T, Koshkin\u00a0VS, Murgi\u0107\u00a0J, Mileti\u0107\u00a0M, Frobe\u00a0A, Johnson\u00a0J, Zakharia\u00a0Y, Alva\u00a0A, Nguyen\u00a0CB, Hui\u00a0G, Drakaki\u00a0A, Rodriguez-Vida\u00a0A, Rey-C\u00e1rdenas\u00a0M, Castellano\u00a0D, Buznego\u00a0LA, Duran\u00a0I, Barrera\u00a0RM, Marmolejo\u00a0D, McKay\u00a0RR, Stewart\u00a0TF, Barata\u00a0P, Epstein\u00a0IB, Bellmunt\u00a0J, Yu\u00a0EY, Raychaudhuri\u00a0R, Nadal\u00a0R, Vakar-Lopez\u00a0F, Gupta\u00a0S, Wright\u00a0JL, Khaki\u00a0AR, Grivas\u00a0P (2025) Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes. Clin Genitourin Cancer 23(4):102356","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2775_CR52","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/bju.15510","volume":"130","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi\u00a0M, Narita\u00a0S, Matsui\u00a0Y, Kanda\u00a0S, Hidaka\u00a0Y, Abe\u00a0H, Tsuzuki\u00a0T, Ito\u00a0K, Kojima\u00a0T, Kato\u00a0M, Hatakeyama\u00a0S, Matsushita\u00a0Y, Naito\u00a0S, Shiga\u00a0M, Miyake\u00a0M, Muro\u00a0M, Nakanishi\u00a0S, Kato\u00a0Y, Shibuya\u00a0T, Hayashi\u00a0T, Yasumoto\u00a0H, Yoshida\u00a0T, Uemura\u00a0M, Taoka\u00a0R, Kamiyama\u00a0M, Morita\u00a0S, Habuchi\u00a0T, Ogawa\u00a0O, Nishiyama\u00a0H, Kitamura\u00a0H, Kobayashi\u00a0T, Japan Urological Oncology Group (2022) Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis. BJU Int 130(2):226\u2013234","journal-title":"BJU Int"},{"issue":"6","key":"2775_CR53","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00345-020-03362-1","volume":"39","author":"S Zamboni","year":"2021","unstructured":"Zamboni\u00a0S, Afferi\u00a0L, Soria\u00a0F, Aziz\u00a0A, Abufaraj\u00a0M, Poyet\u00a0C, Necchi\u00a0A, D\u2019Andrea\u00a0D, Simone\u00a0G, Ferriero\u00a0M, Di Trapani\u00a0E, Simeone\u00a0C, Antonelli\u00a0A, Gallina\u00a0A, Montorsi\u00a0F, Briganti\u00a0A, Colombo\u00a0R, Gandaglia\u00a0G, Mattei\u00a0A, Baumeister\u00a0P, Mordasini\u00a0L, Hendricksen\u00a0K, Voskuilen\u00a0CS, Rink\u00a0M, Shariat\u00a0SF, Xylinas\u00a0E, Moschini\u00a0M (2021) Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. World J Urol 39(6):1947\u20131953","journal-title":"World J Urol"},{"key":"2775_CR54","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt\u00a0J, de Wit\u00a0R, Vaughn\u00a0DJ et\u00a0al (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 376:1015\u20131026","journal-title":"N Engl J Med"},{"key":"2775_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JU.0000000000000761","volume":"204","author":"NJ Miller","year":"2020","unstructured":"Miller\u00a0NJ, Khaki\u00a0AR, Diamantopoulos\u00a0LN et\u00a0al (2020) Histological Subtypes and Response to PD-1\/PD-L1 Blockade in Advanced Urothelial Cancer: A\u00a0Retrospective Study. J\u00a0Urol 204:63\u201370","journal-title":"J Urol"},{"key":"2775_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.humpath.2018.05.022","volume":"80","author":"U Zinnall","year":"2018","unstructured":"Zinnall\u00a0U, Weyerer\u00a0V, Comp\u00e9rat\u00a0E et\u00a0al (2018) Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Hum Pathol 80:55\u201364","journal-title":"Hum Pathol"},{"issue":"18","key":"2775_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184411","volume":"14","author":"S Rodler","year":"2022","unstructured":"Rodler\u00a0S, Eismann\u00a0L, Schlenker\u00a0B, Casuscelli\u00a0J, Brinkmann\u00a0I, Sendelhofert\u00a0A, Waidelich\u00a0R, Buchner\u00a0A, Stief\u00a0C, Schulz\u00a0GB, Ledderose\u00a0S (2022) Expression of Nectin\u20114 in Variant Histologies of Bladder Cancer and Its Prognostic Value-Need for Biomarker Testing in High-Risk Patients? Cancers (Basel) 14(18):4411","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2775_CR58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","volume":"29","author":"JH Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits\u00a0JH, Lombardo\u00a0KA, Parimi\u00a0V, Kamanda\u00a0S, Choi\u00a0W, Hahn\u00a0NM, McConkey\u00a0DJ, McGuire\u00a0BM, Bivalacqua\u00a0TJ, Kates\u00a0M, Matoso\u00a0A (2021) Expression of Nectin\u20114 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes. Appl Immunohistochem Mol Morphol 29(8):619\u2013625","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"2775_CR59","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.clgc.2023.05.014","volume":"21","author":"F Ghali","year":"2023","unstructured":"Ghali\u00a0F, Vakar-Lopez\u00a0F, Roudier\u00a0MP, Garcia\u00a0J, Arora\u00a0S, Cheng\u00a0HH, Schweizer\u00a0MT, Haffner\u00a0MC, Lee\u00a0JK, Yu\u00a0EY, Grivas\u00a0P, Montgomery\u00a0B, Hsieh\u00a0AC, Wright\u00a0JL, Lam\u00a0HM (2023) Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin\u20114 and Trop\u20112 in Variant Histology: A Rapid Autopsy Study. Clin Genitourin Cancer 21(6):669\u2013678","journal-title":"Clin Genitourin Cancer"},{"key":"2775_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154072","volume":"237","author":"M Miyake","year":"2022","unstructured":"Miyake\u00a0M, Miyamoto\u00a0T, Shimizu\u00a0T, Ohnishi\u00a0S, Fujii\u00a0T, Nishimura\u00a0N, Oda\u00a0Y, Morizawa\u00a0Y, Hori\u00a0S, Gotoh\u00a0D, Nakai\u00a0Y, Torimoto\u00a0K, Tanaka\u00a0N, Fujimoto\u00a0K (2022) Tumor expression of Nectin-1\u20114 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin\u20114 expression. Pathol Res Pract 237:154072","journal-title":"Pathol Res Pract"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02775-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:03:36Z","timestamp":1773237816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02775-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2775"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02775-x","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.T.\u00a0Gaisa, H.\u00a0Reis und A.\u00a0Heidenreich geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}